Results

1–10 of 15 results for age-related macular degeneration neovascular

Canadian Treat-and-Extend Trial With Ranibizumab in nAMD Patients: CANTREAT 36-Month Extension Results
Peter J. Kertes, MD, FRCS(C)
Annual Meeting Talks
2020
Pharmacokinetic Profile of the Port Delivery System With Ranibizumab: From PRN Refills in Phase 2 Ladder to Fixed 24-Week Refills In Phase 3 Archway
Dilsher S. Dhoot, MD
Annual Meeting Talks
2020
Updated Safety and Efficacy Results From the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) for Neovascular AMD
Carl C. Awh, MD, FASRS
Updates from the Field
2021
Do Anti-VEGF Injections Affect the Development of Neovascular AMD in Fellow Eyes? A Meta-analysis of Clinical Trials
Robert L. Avery, MD
Annual Meeting Talks
2018
The Cilioretinal Artery is Protective Against Choroidal Neovascularization in Age-Related Macular Degeneration
Glenn C. Yiu, MD, PhD
Annual Meeting Talks
2018
Comparing Outcomes of Standard and Reduced-Fluence Photodynamic Therapy in the Treatment of Polypoidal Choroidal Vasculopathy
Colin S Tan, MBBS, MMed (Ophth), FRCSEd (Ophth)
Annual Meeting Talks
2018
Prophylactic Ranibizumab for Exudative AMD in Vulnerable Eyes With Nonexudative AMD Trial (PREVENT) A Prospective Controlled Clinical Trial
Maziar Lalezary, MD
Annual Meeting Talks
2018
OCT Angiography (OCTA) Monitors The Influence of Different VEGF-I Drugs on a Specific CNVM
Anne M. Hanneken, MD
Annual Meeting Talks
2018
A Real-World Analysis in 49,485 Eyes of Visual Acuity Outcomes and Anti-VEGF Therapy Intensity in Neovascular AMD Patients
David F. Williams, MD, MBA
Annual Meeting Talks
2018
Percentage of Patients Maintained on Quarterly Anti-VEGF Dosing for the Treatment of Neovascular Age-Related Macular Degeneration Across Key Clinical Trials
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2018